Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Travere Therapeutics, Inc. (RTRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/14/2021 |
8-K
| Quarterly results |
| 04/13/2017 |
8-K
| Form 8-K - Current report |
| 03/27/2017 |
8-K
| Form 8-K - Current report |
| 07/19/2016 |
8-K
| Appointed a new director |
| 04/01/2015 |
8-K
| Appointed a new director |
| 03/04/2015 |
8-K
| Appointed a new director |
| 11/14/2013 |
8-K
| Appointed a new director|
Docs:
|
"Jeffrey Paley, MD, Joins Retrophin Inc.’s Board of Directors – Retrophin, Inc. today announced that it has appointed Jeffrey Paley, MD to its Board of Directors, effective November 15, 2013. This latest appointment brings the Company’s Board to five members. Commenting on today’s news, Martin Shkreli, Founder, President and Chief Executive Officer of Retrophin, noted, “We are delighted to welcome Jeff as the newest member of our Board of Directors. Retrophin is currently in an expansion phase and Jeff’s extensive clinical expertise, as well as his experience working with analysts and investors, will be invaluable. We look forward to Jeff’s joining our Board and for his help in guiding Retrophin in further developing its Research and Development program and pursuing strategic financings and..." |
|
|
|